Postoperative Finotonlimab Maintenance
Phase 2
Postoperative Finotonlimab Maintenance is one of 7 therapeutic programs targeting Head and Neck Squamous Cell Carcinoma (HNSCC). It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
13 competitors in Head and Neck Squamous Cell Carcinoma (HNSCC)
#DrugCompanyPhaseTrials
1Libtayo
RegeneronPhase 2
Beyfortus
BeiGenePhase 2
Keytruda
Merck & Co.Phase 1
Soc
PfizerPreclinical
Postoperative Finotonlimab Maintenance
YYanjie Zhang, MD
Phase 2
Axelopran
HHealthPartners Institute
Preclinical
Pembolizumab
SShanghai JMT-Bio Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2[1]
- Company
- YYanjie Zhang, MD